This page enables investors and potential investors alike to access core management and financial information in compliance with Rule 26 of the AIM Rules for Companies.
This information was last updated on 10th June 2018.
For information on the following topics, please click on the links below.
Corporate governance and Board responsibilities
Incorporation and operation
Annual report and accounts
Shares in issue
There are no restrictions on transfer of AIM securities of Allergy Therapeutics plc (AGY).
If you require further information about Allergy Therapeutics, please contact us.
This website is owned by Allergy Therapeutics plc and hosted by Mass Integrated Marketing Limited.